Core Viewpoint - 瑞迈特医疗科技股份有限公司的股价在11月7日上涨5.07%，截至发稿时为90.60元/股，总市值达到81.18亿元 [1] Company Overview - 瑞迈特成立于2001年7月27日，上市于2022年11月1日，主要业务包括研发、生产和销售呼吸健康领域的医疗设备及相关服务 [1] - 公司专注于为阻塞型睡眠呼吸暂停低通气综合征(OSA)和慢性阻塞性肺疾病(COPD)患者提供全周期、多场景的治疗服务 [1] - 主营业务收入构成：家用呼吸诊疗产品占64.19%，耗材占32.67%，医用产品占3.05%，其他占0.10% [1] Shareholder Information - 汇添富医药保健混合基金在瑞迈特的十大流通股东中占据一席，持有129.53万股，占流通股的2.3% [2] - 该基金在三季度新进十大流通股东，今日浮盈约566.03万元 [2] Fund Performance - 汇添富医药保健混合基金的最新规模为24.86亿元，今年以来收益为30.45%，近一年收益为20.86% [2] - 基金经理郑磊的任职时间为10年329天，任职期间最佳基金回报为53.42% [3]

Core Viewpoint - Haofan Bio experienced a 5.23% increase in stock price, reaching 58.20 CNY per share, with a trading volume of 116 million CNY and a turnover rate of 4.82%, resulting in a total market capitalization of 6.286 billion CNY [1] Company Overview - Suzhou Haofan Bio Co., Ltd. is located at Changting Road 1, Suzhou High-tech Zone, Jiangsu Province, and was established on December 2, 2003. The company went public on July 12, 2023. Its main business involves the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] Shareholder Information - Among the top ten circulating shareholders of Haofan Bio, a fund under Huatai PineBridge holds a position. The Huatai Medical and Health Mixed Fund (470006) entered the top ten circulating shareholders in the second quarter, holding 602,500 shares, which accounts for 1.5% of the circulating shares. It is estimated that the fund has earned approximately 1.7411 million CNY in floating profit today [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY. Year-to-date returns stand at 35.59%, ranking 1703 out of 8254 in its category; the one-year return is 41.87%, ranking 3403 out of 8037; and since inception, the return is 171.31% [2] - The fund manager of Huatai Medical and Health Mixed Fund (470006) is Zheng Lei, who has a cumulative tenure of 10 years and 262 days. The total asset scale under his management is 7.072 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -21.99% [2]